The unique, all-in-one point of care test for the qualitative detection of IgG and IgM antibodies to SARS-CoV-2 virus in whole blood, serum, or plasma samples.
Unlike standard, multi-component rapid test kits, the AtomoRapid™ COVID-19 (IgG/IgM) Rapid Antibody Test is a single-use, handheld, integrated device that is simple to use, safe, and convenient, giving an accurate result in just 15 minutes.
The AtomoRapid™ COVID-19 (IgG/IgM) Rapid Antibody Test incorporates Atomo’s award-winning ‘Galileo’ integrated diagnostic test platform – designed and developed in Australia – for peerless safety and utility.
The Galileo platform simplifies the test procedure by removing the need for multiple test components, eliminating common user errors and improving test performance:
Developed in partnership with French biotechnology specialist NG Biotech, the AtomoRapid™ COVID-19 (IgG/IgM) Rapid Antibody Test has demonstration excellent performance in multiple independent clinical evaluations internationally.
* Van der Werf S et al (2020). Performance evaluation report for the detection of anti SARS-CoV-2 antibodies. National Reference Centre for Respiratory Infection Viruses (including influenza), Institut Pasteur, Paris.
The AtomoRapid™ COVID-19 (IgG/IgM) Rapid Antibody Test is listed on the Australian Register of Therapeutic Goods (ARTG,341411) and is available for use by accredited pathology laboratories; registered medical practitioners; healthcare professionals in residential and aged care facilities; Commonwealth, State, or Territory departments of health, and agencies acting of their behalf.
*Product launches Mid-October. Pre-Order Now While Stocks Last.